Human TRANCE/TNFSF11/RANK L Antibody

Name: Human TRANCE/TNFSF11/RANK L Antibody
Brand: R&D Systems
SKU: AF626
Price: 123 USD

Catalog # AF626 | R&D Systems, Inc. a Bio-Techne Brand

Citations (3)

Product Datasheet / COA / SDS

100% Guarantee

Product Summary
Scientific Data
Applications
Preparation & Storage
Background
Product Documents
Specific Notices

Key Product Details

Species Reactivity

Human

Applications

Neutralization, Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG

Product Summary for Human TRANCE/TNFSF11/RANK L Antibody

Immunogen

S. frugiperda insect ovarian cell line Sf 21-derived recombinant human TRANCE/TNFSF11/RANK L
Gln73-Asp317 (Ala194Gly)
Accession # O14788

Specificity

Detects human TRANCE/TNFSF11/RANK L in direct ELISAs and Western blots.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Scientific Data Images for Human TRANCE/TNFSF11/RANK L Antibody

Osteoclast-Like Cell Form-ation Induced by TRANCE/ TNFSF11/RANK L and Neutralization by Human TRANCE/TNFSF11/RANK L Antibody.

In the presence of Recombinant Mouse M-CSF (20 ng/mL, 416-ML), Recombinant Human TRANCE/ TNFSF11/RANK L (390-TN) induces osteoclast-like cell formation in RAW 264.7 mouse macrophages in a dose-dependent manner (orange line), as measured by TRAP (tartrate-resistant acid phosphatase) solution assay. Under these conditions, osteoclast-like cell formation elicited by Recombinant Human TRANCE/TNFSF11/ RANK L (10 ng/mL) is neutral-ized (green line) by increasing concentrations of Goat Anti-Human TRANCE/TNFSF11/ RANK L Antigen Affinity-purified Poly-clonal Antibody (Catalog # AF626). The ND₅₀ is typically 0.01-0.04 µg/mL.

Applications for Human TRANCE/TNFSF11/RANK L Antibody

Application

Recommended Usage

Western Blot

0.1 µg/mL
Sample: Recombinant Human TRANCE/TNFSF11/RANK L (Truncated) (Catalog # 390-TN)

Neutralization

Measured by its ability to neutralize TRANCE/TNFSF11/RANK L-induced osteoclast-like cell formation in RAW 264.7 mouse macrophages. The Neutralization Dose (ND₅₀) is typically 0.01-0.04 µg/mL in the presence of 10 ng/mL Recombinant Human TRANCE/TNFSF11/RANK L.

Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation and Storage

Purification

Antigen Affinity-purified

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TRANCE/TNFSF11/RANK L

RANK Ligand (receptor activator of NF-kappa B ligand [RANKL], also called TNF-related activation-induced cytokines (TRANCE), osteoprotegerin ligand [OPGL], and osteoclast differentiation factor [ODF]), is a member of the tumor necrosis factor (TNF) family. RANK Ligand was originally identified as an immediate early gene upregulated by T cell receptor stimulation. The human RANK Ligand cDNA encodes a type II transmembrane protein of 317 amino acids with a predicted cytoplasmic domain of 47 amino acids, a 21 amino acids transmembrane region, and an extracellular domain of 249 amino acids. The extracellular domain contains two potential N‑linked glycosylation sites. Mouse and human RANK Ligand share 85% amino acid identity. RANK Ligand is primarily expressed in T cells and T cell rich organs, such as thymus and lymph nodes. The multi-functions of RANK Ligand include induction of activation of the c-jun N‑terminal kinase, enhancement of T cell growth and dendritic cell function, induction of osteoclastogenesis, and lymph node organogenesis. RANK is the cell surface signaling receptor of RANK Ligand. RANK has been shown to undergo receptor clustering during signal transduction. Osteoprotegerin, a soluble member of the TNF receptor family which binds RANK Ligand, is a naturally occurring decoy receptor that counterbalances the effects of RANK Ligand.

References

Wong, B.R. et al. (1997) J. Biol. Chem. 272:25190.
Anderson, D.M. et al. (1997) Nature 390:175.
Nakagawa, N. et al. (1998) Biochem. Biophys. Res. Commun. 245:382.
Kong, Y-Y. et al. (1999) Nature 397:315.

Long Name

TNF-related Activation-induced Cytokine

Alternate Names

CD254, ODF, OPGL, RANK L, RANKL, TNFSF11

Entrez Gene IDs

102137946 (Cynomolgus Monkey); 8600 (Human); 21943 (Mouse); 117516 (Rat)

Gene Symbol

TNFSF11

UniProt

O14788

Product Documents for Human TRANCE/TNFSF11/RANK L Antibody

Product Datasheets

Download Product Datasheets

COA

SDS

Download SDS

Product Specific Notices for Human TRANCE/TNFSF11/RANK L Antibody

For research use only

Citations for Human TRANCE/TNFSF11/RANK L Antibody (3)

Showing 1 - 3 of 3 citations Showing All

Filter By:

Search Title:

Citations are publications that use Bio-Techne products. Selected citations for Human TRANCE/TNFSF11/RANK L Antibody include:

Sample Types: Protein
Applications: Binding Assay

Justin R Savage (2016-06-16), A Modified Glycosaminoglycan, GM-0111, Inhibits Molecular Signaling Involved in Periodontitis PLoS ONE, 2016-011(6):e0157310.
PMID: 27308827
Species: Human
Sample Types: Cell Lysates
Applications: Western Blot

Buckle et al. (2012-08-29), Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma. PLoS ONE, 2012-07(8):e41127.
PMID: 22952578
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P

Grimaud E et al. (2003-11-01), Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am. J. Pathol., 2003-1163(5):2021-31.
PMID: 14578201

There are no citations that match your criteria.